Clinical Trials · NCT07444983
Rezvilutamide for High-Risk Prostate Cancer After Surgery
- Phase
- N/A
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Enrollment
- 33
- Start date
- Feb 2026
- Locations
- 1 site, China
- Primary endpoint
- 3-year Biochemical Recurrence-Free Survival (BCRFS) Rate.